Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.70 |
| ▸ | NR5A2 | O00482 | 2/20 | 0.56 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.49 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695210 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL18025185 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL4991825 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL20494173 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL22115876 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL25403277 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL4991832 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL21713133 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL21641641 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP | |
| SCHEMBL9917194 | 0.89 | FABP3 (0.88) | FABP3NR5A2NR5A1SMN1; SMN2SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188475-A1 | REAGENTS FOR INDUCING AN IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-06-18 | — | — | US | disclosed |
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-20110033522-A1 | REAGENTS FOR INDUCING AN IMMUNE RESPONSE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | MAG, FABP7, PMP22 | FABP3 84/4885NR5A2 2874/4885NR5A1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.